Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants
To the Editor: The Food and Drug Administration (FDA) approved voriconazole for the
treatment of invasive aspergillosis partly on the basis of data published in a report in the
Journal, 1 which showed an improved clinical response and improved survival with
voriconazole treatment as compared with a strategy of initial treatment with amphotericin B
deoxycholate. In patients with neutropenia and persistent fever, the use of voriconazole as
empirical therapy failed to fulfill criteria for noninferiority as compared with liposomal …
treatment of invasive aspergillosis partly on the basis of data published in a report in the
Journal, 1 which showed an improved clinical response and improved survival with
voriconazole treatment as compared with a strategy of initial treatment with amphotericin B
deoxycholate. In patients with neutropenia and persistent fever, the use of voriconazole as
empirical therapy failed to fulfill criteria for noninferiority as compared with liposomal …
To the Editor: The Food and Drug Administration (FDA) approved voriconazole for the treatment of invasive aspergillosis partly on the basis of data published in a report in the Journal, 1 which showed an improved clinical response and improved survival with voriconazole treatment as compared with a strategy of initial treatment with amphotericin B deoxycholate. In patients with neutropenia and persistent fever, the use of voriconazole as empirical therapy failed to fulfill criteria for noninferiority as compared with liposomal amphotericin B,2 and the results of that trial generated substantial discussion after the FDA declined approval of the drug for that indication. . . .
The New England Journal Of Medicine